Advertisement

Advertisement

APVO Stock Latest News

Aptevo AML data ‘highly encouraging,’ says Roth Capital

The FlyAptevo AML data ‘highly encouraging,’ says Roth Capital

Aptevo Reports Promising Mipletamig Data in TP53-Mutant AML

PremiumCompany Announcements

Aptevo Reports Promising Mipletamig Data in TP53-Mutant AML

2d ago

Aptevo Therapeutics’ mipletamig triplet shows 93% benefit in leukemia

PremiumThe Fly

Aptevo Therapeutics’ mipletamig triplet shows 93% benefit in leukemia

2d ago

Aptevo Shareholders Back Board, Auditor and Incentive Plan

PremiumCompany Announcements

Aptevo Shareholders Back Board, Auditor and Incentive Plan

14d ago

Aptevo Therapeutics files to sell 6.44M shares of common stock for holders

PremiumThe Fly

Aptevo Therapeutics files to sell 6.44M shares of common stock for holders

14d ago

Aptevo Therapeutics announces exercise of warrants, PIPE for $4.5M in proceeds

PremiumThe FlyAptevo Therapeutics announces exercise of warrants, PIPE for $4.5M in proceeds

19d ago

Aptevo Therapeutics reports $9.8M in cash, cash equivalents as of June 30

The Fly

Aptevo Therapeutics reports $9.8M in cash, cash equivalents as of June 30

20d ago

Aptevo Therapeutics Raises Capital Through Warrant-Induced Financing

Company Announcements

Aptevo Therapeutics Raises Capital Through Warrant-Induced Financing

22d ago

Aptevo Therapeutics Unveils New Solid Tumor Strategy

PremiumCompany Announcements

Aptevo Therapeutics Unveils New Solid Tumor Strategy

1M ago

Aptevo files patent application for Nectin-4 x PD-L1 dual-targeting backbone

PremiumThe Fly

Aptevo files patent application for Nectin-4 x PD-L1 dual-targeting backbone

1M ago

Aptevo Therapeutics Secures Grant for APVO451 Development

PremiumCompany Announcements

Aptevo Therapeutics Secures Grant for APVO451 Development

2M ago

Aptevo Therapeutics awarded $1.5M research grant from Andy Hill CARE Fund

PremiumThe Fly

Aptevo Therapeutics awarded $1.5M research grant from Andy Hill CARE Fund

2M ago

Aptevo Therapeutics appoints Janatpour as SVP, CSO

PremiumThe FlyAptevo Therapeutics appoints Janatpour as SVP, CSO

3M ago

Aptevo Forms Strategic Radiopharmaceutical Collaboration with Niowave

Company Announcements

Aptevo Forms Strategic Radiopharmaceutical Collaboration with Niowave

3M ago

Aptevo, Niowave launch collab for radiopharmaceutical oncology programs

The Fly

Aptevo, Niowave launch collab for radiopharmaceutical oncology programs

3M ago

Aptevo Therapeutics reports Q1 cash and cash equivalents $14.5M

PremiumThe Fly

Aptevo Therapeutics reports Q1 cash and cash equivalents $14.5M

4M ago

Aptevo reports 87% clinical benefit in frontline AML patients in RAINIER trial

PremiumThe Fly

Aptevo reports 87% clinical benefit in frontline AML patients in RAINIER trial

4M ago

Aptevo Highlights Strong Phase 1b AML Trial Results

PremiumCompany Announcements

Aptevo Highlights Strong Phase 1b AML Trial Results

4M ago

Aptevo Therapeutics reports FY25 EPS ($87.27) vs. ($31,460.23) last year

PremiumThe Fly

Aptevo Therapeutics reports FY25 EPS ($87.27) vs. ($31,460.23) last year

5M ago

Aptevo Therapeutics sees cash runway into 4Q26

PremiumThe FlyAptevo Therapeutics sees cash runway into 4Q26

5M ago

Aptevo Reports Promising Interim Data for AML Therapy

Company Announcements

Aptevo Reports Promising Interim Data for AML Therapy

6M ago

Aptevo Therapeutics announces interim data for mipletamig combination

The Fly

Aptevo Therapeutics announces interim data for mipletamig combination

6M ago

Trending

S&P 500

―

Dow Jones

―

Nasdaq 100

―

More Trending Stocks >